血清NOX2作为HBV相关疾病的新生物标志物候选者

StephenW

Am J Transl Res. 2018 Aug 15;10(8):2350-2361. eCollection 2018.
Serum NOX2 as a new biomarker candidate for HBV-related disorders.
Xiong Y1, Ye Y2, Li P2, Xiong Y2, Mao J2, Huang Y2, Chen W2, Wang B2.
Author information

1
    Department of Laboratory Medicine, Chongqing Health Center for Women and Children Chongqing 401147, China.
2
    Department of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University Chongqing 400010, China.

Abstract

Growing evidence supports the notion that serum NAPDH oxidase 2 (NOX2) is an important regulator that contributes to the initiation and progression of various types of diseases. However, so far, it remains elusive about the relationship between levels of serum NOX2 and HBV-related diseases. The overall purpose of the study is to get a better insight into whether or not serum NOX2 is involved in HBV-related disorders. Serum levels of NOX2, from 105 patients with chronic hepatitis B, 58 patients with HBV-related cirrhosis, 48 patients with HBV-related hepatocellular carcinoma and 104 healthy individuals, were measured with sandwich ELISA kits that we developed. In this study, we found that NOX2 values were significantly higher in patients compared to healthy control (P < 0.01) and that the levels of serum NOX2 were significantly correlated with the serum levels of superoxide dismutase (SOD), interleukin-6 (IL-6), interferon-stimulated gene 15 (ISG15), alkaline phosphatase (ALP) and gamma glutamyl transpeptidase (GGT) in chronic hepatitis B, cirrhosis and hepatocellular carcinoma patients. Interestingly, we found that a significant positive correlation between NOX2 and HBV viral load only in patients with chronic hepatitis B and cirrhosis. Therefore, Serum NOX2 levels maybe an important indicator of the pathogenesis of progression of HBV-related disorders.
KEYWORDS:

Hepatitis B virus; NOX2; ROS; chronic hepatitis B; cirrhosis; hepatocellular carcinoma

PMID:
    30210675

StephenW

Am J Transl Res。 2018年8月15日; 10（8）：2350-2361。 eCollection 2018。
血清NOX2作为HBV相关疾病的新生物标志物候选者。
熊Y 1，叶Y 2，李P2，熊Y 2，毛J2，黄Y2，陈W2，王B2。
作者信息

1
    重庆市妇女儿童健康中心检验科，重庆401147
2
    重庆医科大学附属第二医院检验科，重庆400010

抽象

越来越多的证据支持血清NAPDH氧化酶2（NOX2）是一种重要的调节因子，它可以促进各种疾病的发生和发展。然而，到目前为止，血清NOX2水平与HBV相关疾病之间的关系仍然难以捉摸。该研究的总体目的是更好地了解血清NOX2是否与HBV相关的疾病有关。采用我们开发的夹心ELISA试剂盒测定105例慢性乙型肝炎患者，58例HBV相关性肝硬化患者，48例HBV相关性肝细胞癌患者和104例健康个体的血清NOX2水平。在本研究中，我们发现患者的NOX2值显着高于健康对照组（P <0.01），血清NOX2水平与血清​​超氧化物歧化酶（SOD），白细胞介素-6（IL-）水平显着相关。 6），干扰素刺激的基因15（ISG15），碱性磷酸酶（ALP）和γ谷氨酰转肽酶（GGT）在慢性乙型肝炎，肝硬化和肝细胞癌患者中。有趣的是，我们发现只有慢性乙型肝炎和肝硬化患者的NOX2和HBV病毒载量之间存在显着的正相关。因此，血清NOX2水平可能是HBV相关疾病进展发病机制的重要指标。
关键词：

乙型肝炎病毒; NOX2; ROS;慢性乙型肝炎;肝硬化;肝细胞癌

结论：
    30210675